Escuche esta historia
--:--
2:54
The EMA approved the pill Molnupiravir in case of emergency against COVID-19
The specialists of the European Medicines Agency (EMA) have supported on Friday the possible use of the crisis of the antiviral molnupiravir to treat the Coronavirus, which will be regulated by the election of public experts in the nations of the European Union (EU), before the authority's license.
The European regulator focuses on this as a benefit to help public specialists in order to place this pill before accepting its development approval, for example, in a crisis environment, "taking into account the increase in diseases and massive contagions of Coronavirus "in the EU.
The drug known as Lagevrio and accessible in the case structure, must be taken twice a day for 5 days by adults with Coronavirus who do not need supplemental oxygen and who are patients in danger of creating a serious infection.
It suggests that this drug, which does not yet have an authority permit for use in the EU and remains under continuous survey, is regulated "immediately after determination" of Coronavirus and within 5 days of starting the indication, in light of panel finishes for human use catering items (CHMP).
The office has studied the accessible information on the quality of the medication and the results of the completed and in-progress considerations, as well as the results of breakdown of the main concentrate in non-hospitalized and unvaccinated patients with some basic condition that puts them in danger of extreme Coronavirus.
As indicated by these data, Lagevrio reduces the risk of hospitalization and death when administered in an 800 mg serving twice daily and treatment started within five days of onset.
Regarding well-being, the most recognized side effects revealed during treatment and within about fourteen days after the last serving of molnupiravir were loose bowel, sickness, tipsiness, and brain pain, all mild to address.
Tests by research centers on babies have shown that high portions of this drug can influence the development and improvement of the embryo, says the European office.
This oral antiviral, created by the American pharmaceutical organization Merck Sharp and Dohme in partnership with the biotechnological organization Ridgeback Biotherapeutics, decreases the ability to duplicate the infection in the body.
European countries can use this advice from the EMA to assist public proposals on the possible use of this medicine, pending further evaluation by the organization's specialists and the possible request of the medicine organization of a European permission for its use, which does not yet have an approval date.
The EMA is giving this advice in line with the head of the organization, Emer Cooke, and after discussions with specialists from across the European organization of public medication controllers, who considered this proposal vital given the large number of contaminations and hospitalizations for Coronavirus.
